Skip to main content

Eight-Week Randomized, Double-Blind, Placebo-Controlled 2-Site Trial Assessing the Efficacy and Safety of Mixed Amphetamine Salt as an Adjunctive Therapy for Bipolar Depression

In brief

Add-on amphetamine cut depression scores 62% in a small bipolar trial

In an 8-week trial of 32 adults with bipolar depression, symptoms fell by an average of 62% with mixed amphetamine salts added to usual treatment, versus 15% with placebo; remission occurred in 63% versus 9%. Mania ratings did not differ during the controlled phase, but one person switched to mania during the open-label extension, so larger, longer trials are needed to clarify benefits and risks.

Journal
The Journal of clinical psychiatry (Q1)
Published
16 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Mark A Frye, Jorge A Sanchez-Ruiz, Nicolas Nunez, Karin Lindstrom, Vanessa K Pazdernik, Nicole Mori, et al.
PMID
43055653
DOI
10.4088/JCP.26m16446

Why clinicians should know about it

Abstract

Objective: This study examined the efficacy and safety of adjunctive mixed d-amphetamine/l-amphetamine salt (MAS; Mydayis) in adults with DSM-IV-TR-confirmed bipolar I or II depression. Methods: In this 8-week, randomized, placebo-controlled 2-site study of adjunctive MAS, the primary outcome was baseline-to-end point change in the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes included, in part, treatment response and remission (≥50% MADRS reduction, MADRS <10) and illness improvement as measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP). The primary safety assessment was the Young Mania Rating Scale (YMRS). The 8-week controlled trial was followed by an 8-week open-label extension. Results: Thirty-two (14 with bipolar I disorder, 18 with bipolar II disorder; 10 male, 22 female; mean age=38.2 y) patients enrolled in the study. Baseline symptoms (MADRS = 27.0±6.3, Quick Inventory of Depressive Symptomatology-Clinician-Rated = 15.3±3.2, Quick Inventory of Depressive Symptomatology-Self-Report = 14.8±4.7, and YMRS = 4.0) were consistent with moderate depression and absence of hypomania. Baseline demographics showed no significant group differences. In age-adjusted analyses, participants receiving adjunctive MAS (n = 15) showed significantly greater improvement on MADRS compared to placebo (n = 17, mean percent reduction: 62.3% vs 15.4%; P= .002), with higher rates of remission (63.3% vs 8.5%; P= .002) and response (79.5% vs 7.3%; P <.001). CGI-BP ratings of "much improved" or "very much improved" were higher with MAS (67.0% vs 10.2%; P= .001). No significant differences were observed in YMRS (last observation 2.9 vs 3.3; P= .72). The open-label extension (n = 24) showed maintenance of response, with 1 participant experiencing a switch to mania and 2 participants with drug misuse. Conclusions: Adjunctive MAS was associated with effective reduction in depression symptoms with broad safety profile for most participants. Secondary analyses are encouraged to examine differential response rates by mood stabilizer and item analyses of attention and eating behavior. Trial Registration: ClinicalTrials.gov identifier: NCT04235686.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.